Sanofi Wins FDA Approval for Infilbray, First Medicine for Neurological Type 3 Gaucher Disease

SentiSense · Published · Updated

The FDA approved Sanofi's Infilbray (venglustat), a once-daily oral pill, as the first medicine to treat the neurological manifestations of Type 3 Gaucher disease in adults and children weighing at least 15 kg. Approval rests on the 43-patient LEAP2MONO trial, which showed superiority over enzyme therapy on a combined motor and cognitive endpoint.

SNY said the FDA approved Infilbray (venglustat) as the first medicine to treat the neurological manifestations of Type 3 Gaucher disease, in adults and pediatric patients weighing at least 15 kg. Infilbray is a once-daily oral glucosylceramide synthase inhibitor designed to cross the blood-brain barrier, which matters because the standard intravenous enzyme replacement therapies address the systemic disease but not its neurological effects.

The approval is based on the Phase 3 LEAP2MONO trial, a double-blind study that randomized 43 patients aged 12 and older, all stable on enzyme replacement therapy for at least three years, to Infilbray or intravenous imiglucerase every two weeks. The primary endpoint, a combined test of change at Week 52 in motor (mSARA) and cognitive (RBANS) scores, showed superiority for Infilbray with p=0.0137, according to Sanofi's release. The label carries warnings for suicidal ideation, lens opacification in pediatric patients and embryo-fetal toxicity, and diarrhea, nausea and vomiting were among side effects more common on Infilbray.

Regulatory reviews are under way in the EU and Japan, and Sanofi did not disclose launch timing or pricing in its announcement.

What to watch: pricing and launch timing in the U.S., decisions in the EU and Japan, and whether real-world use confirms the trial benefit in a very small, rare-disease population.

Related Stocks

Powered by SentiSense - Intelligent Market Analysis